SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-22-020587
Filing Date
2022-08-03
Accepted
2022-08-03 16:04:23
Documents
15
Period of Report
2022-08-03
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K mrtx-20220803.htm   iXBRL 8-K 40697
2 EX-99.1 exhibit991-q22022.htm EX-99.1 86880
7 miratilogo2020a.jpg GRAPHIC 11205
  Complete submission text file 0001628280-22-020587.txt   320545

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT mrtx-20220803.xsd EX-101.SCH 2151
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT mrtx-20220803_def.xml EX-101.DEF 15321
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT mrtx-20220803_lab.xml EX-101.LAB 30058
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT mrtx-20220803_pre.xml EX-101.PRE 15974
9 EXTRACTED XBRL INSTANCE DOCUMENT mrtx-20220803_htm.xml XML 10538
Mailing Address 3545 CRAY COURT SAN DIEGO CA 92121
Business Address 3545 CRAY COURT SAN DIEGO CA 92121 858-332-3410
Mirati Therapeutics, Inc. (Filer) CIK: 0001576263 (see all company filings)

IRS No.: 462693615 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35921 | Film No.: 221132487
SIC: 2834 Pharmaceutical Preparations